Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium
- PMID: 32779892
- DOI: 10.1002/pbc.28652
Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium
Abstract
Background: Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders that commonly progress to acute myeloid leukemia (AML). The diagnostics, prognostics, and treatment of adult MDS are established but do not directly translate to children and adolescents. Pediatric MDS is a rare disease, characterized by unique cytogenetics and histology compared with adult MDS, and often arises secondary to germline predisposition or cytotoxic exposures. Our objective was to highlight aspects of diagnosis/management that would benefit from further systematic review toward the development of clinical practice guidelines for pediatric MDS.
Procedure: The North American Pediatric Aplastic Anemia Consortium (NAPAAC) is composed of collaborative institutions with a strong interest in pediatric bone marrow failure syndromes and hematologic malignancies. The NAPAAC MDS working group developed a national survey distributed to 35 NAPAAC institutions to assess data on (1) clinical presentation of pediatric MDS, (2) diagnostic evaluation, (3) criteria for diagnosis, (4) supportive care and treatment decisions, and (5) role of hematopoietic stem cell transplantation (HSCT).
Results: Twenty-eight of 35 institutions returned the survey. Most centers agreed on a common diagnostic workup, though there was considerable variation regarding the criteria for diagnosis. Although there was consensus on supportive care, treatment strategies, including the role of cytoreduction and HSCT, varied across centers surveyed.
Conclusions: There is lack of national consensus on diagnosis and treatment of pediatric MDS. This survey identified key aspects of MDS management that will warrant systematic review toward the goal of developing national clinical practice guidelines for pediatric MDS.
Keywords: aplastic anemia; inherited bone marrow failure syndromes; myelodysplastic syndromes.
© 2020 Wiley Periodicals LLC.
Similar articles
-
Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC).Pediatr Blood Cancer. 2014 May;61(5):869-74. doi: 10.1002/pbc.24875. Epub 2013 Nov 27. Pediatr Blood Cancer. 2014. PMID: 24285674 Free PMC article.
-
Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults.Ann Diagn Pathol. 2020 Apr;45:151459. doi: 10.1016/j.anndiagpath.2019.151459. Epub 2019 Dec 30. Ann Diagn Pathol. 2020. PMID: 32000075
-
Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.Am J Hematol. 2021 Nov 1;96(11):1491-1504. doi: 10.1002/ajh.26310. Epub 2021 Aug 20. Am J Hematol. 2021. PMID: 34342889
-
Myelodysplastic syndromes: the pediatric point of view.Haematologica. 1995 May-Jun;80(3):268-79. Haematologica. 1995. PMID: 7672722 Review.
-
Diagnosis and management of aplastic anemia and myelodysplastic syndrome.Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):153-61. Oncology (Williston Park). 2002. PMID: 12380966 Review.
Cited by
-
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.Clin Case Rep. 2023 Nov 22;11(11):e8190. doi: 10.1002/ccr3.8190. eCollection 2023 Nov. Clin Case Rep. 2023. PMID: 38028059 Free PMC article.
-
Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?Blood Adv. 2024 Jul 9;8(13):3583-3595. doi: 10.1182/bloodadvances.2023012041. Blood Adv. 2024. PMID: 38701350 Free PMC article. Review.
-
Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience.Cancers (Basel). 2025 May 13;17(10):1645. doi: 10.3390/cancers17101645. Cancers (Basel). 2025. PMID: 40427141 Free PMC article.
-
Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal Petechiae.N Engl J Med. 2021 Oct 14;385(16):1511-1520. doi: 10.1056/NEJMcpc2027096. N Engl J Med. 2021. PMID: 34644476 Free PMC article. No abstract available.
-
A Rare Concurrence of Myelodysplastic Neoplasia and Tetrasomy 8 in a 3-Year-Old Bahraini Male.Cureus. 2023 Jul 17;15(7):e41988. doi: 10.7759/cureus.41988. eCollection 2023 Jul. Cureus. 2023. PMID: 37593262 Free PMC article.
References
REFERENCES
-
- Niemeyer CM, Kratz CP, Hasle H. Pediatric myelodysplastic syndromes. Curr Treat Options Oncol. 2005;6(3):209-214.
-
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
-
- Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia. Canada Br J Haematol. 1999;106(4):1027-1032.
-
- Galaverna F, Ruggeri A, Locatelli F. Myelodysplastic syndromes in children. Curr Opin Oncol. 2018;30(6):402-408.
-
- Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387-1397. quiz 518.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous